Skip navigation Wisconsin State Legislature
Up
SPS 10.02(1)(1)  A licensed optometrist, authorized in accordance with ch. Opt 6, may use topical ocular diagnostic pharmaceutical agents to determine the visual efficiency of the human visual system, including refractive and functional abilities, or to diagnose the presence of ocular disease or ocular manifestations of system disease and other departures from normal.
SPS 10.02(2) (2) Diagnostic pharmaceutical agents include:
SPS 10.02(2)(a) (a) Mydriatics.
SPS 10.02(2)(a)1. 1. Phenylephrine 2.5%.
SPS 10.02(2)(a)2. 2. Hydroxyamphetamine 1%.
SPS 10.02(2)(b) (b) Cycloplegics.
SPS 10.02(2)(b)1. 1. Tropicamide 1%.
SPS 10.02(2)(b)2. 2. Cyclopentolate 1%.
SPS 10.02(2)(c) (c) Topical anesthetics.
SPS 10.02(2)(c)1. 1. Benoxinate 0.4%.
SPS 10.02(2)(c)2. 2. Proparacaine 0.5%.
SPS 10.02(2)(c)3. 3. Tetracaine 0.5%.
SPS 10.02(2)(c)4. 4. Benoxinate 0.4% - Fluorescein 0.25% Combination.
SPS 10.02(2)(d) (d) Dyes.
SPS 10.02(2)(d)1. 1. Fluorescein 0.25% - Benoxinate 0.4% Combination.
SPS 10.02(2)(d)2. 2. Rose Bengal.
SPS 10.02(2)(e) (e) Miotics.
SPS 10.02(2)(e)1. 1. Dapiprazole HCl.
SPS 10.02(2)(e)2. 2. Pilocarpine 0.125%.
SPS 10.02(2)(f) (f) Any drug or device that is used for an ophthalmic diagnostic purpose and that is the subject of a new drug application approved by the food and drug administration under section 505 (c) (1) of the federal food, drug and cosmetic act, 21 USC 355, as amended.
SPS 10.02(2)(g) (g) Any drug or device that is used for an ophthalmic diagnostic purpose and that is generally exempt from the new drug application approval requirement contained in section 505 of the federal food, drug and cosmetic act, 21 USC 355, as amended.
SPS 10.02 History History: CR 19-028: cr. Register January 2020 No. 769, eff. 2-1-20; s. 35.17 correction in (2) (e) 2. made under s. 35.17, Stats., Register January 2020 No. 769.
SPS 10.03 SPS 10.03  Therapeutic pharmaceutical agents.
SPS 10.03(1)(1)  A licensed optometrist, authorized in accordance with ch. Opt 6, may prescribe or administer a drug, as specified in sub. (2), for ocular therapeutic purposes.
SPS 10.03(2) (2) For the purposes of this chapter, therapeutic pharmaceutical agents are limited to:
SPS 10.03(2)(a) (a) Oral analgesics.
SPS 10.03(2)(a)1. 1. Acetaminophen.
SPS 10.03(2)(a)2. 2. Aspirin.
SPS 10.03(2)(a)3. 3. Salicylates.
SPS 10.03(2)(a)4. 4. Schedule III, IV and V narcotic analgesics.
SPS 10.03(2)(b) (b) Controlled substances in schedule II with limitations, as specified in s. 961.39 (2m), Stats.
SPS 10.03(2)(c) (c) Topical decongestant agents and decongestant combinations.
SPS 10.03(2)(c)1. 1. Epinephrine HCl.
SPS 10.03(2)(c)2. 2. Hydroxyamphetamine HBr.
SPS 10.03(2)(c)3. 3. Naphazoline HCl.
SPS 10.03(2)(c)4. 4. Oxymetazoline HCl.
SPS 10.03(2)(c)5. 5. Phenylephrine HCl.
SPS 10.03(2)(c)6. 6. Tetrahydrozoline HCl.
SPS 10.03(2)(c)7. 7. Combinations of the agents identified in subds. 1. to 6. with antihistamines or zinc sulfate.
SPS 10.03(2)(d) (d) Antiallergy agents.
SPS 10.03(2)(d)1. 1. Topical and oral antihistamine agents in the following drug categories:
SPS 10.03(2)(d)1.a. a. Alkyamines.
SPS 10.03(2)(d)1.b. b. Ethanolamines.
SPS 10.03(2)(d)1.c. c. Ethylenediamines.
SPS 10.03(2)(d)1.d. d. Phenothiazines.
SPS 10.03(2)(d)1.e. e. Piperazines.
SPS 10.03(2)(d)1.f. f. Piperidines.
SPS 10.03(2)(d)1.g. g. Terfenadines.
SPS 10.03(2)(d)2. 2. Cromolyn sodium, a mast cell stabilizing agent.
SPS 10.03(2)(e) (e) Artificial tear solutions, ophthalmic irrigants and ocular lubricants.
SPS 10.03(2)(f) (f) Hypertonic sodium chloride, a topical hyperosmotic agent.
SPS 10.03(2)(g) (g) Yellow mercuric oxide, a miscellaneous preparation and product.
SPS 10.03(2)(h) (h) Topical anesthetics.
SPS 10.03(2)(h)1. 1. Benoxinate HCl.
SPS 10.03(2)(h)2. 2. Benoxinate HCl and sodium fluorescein.
SPS 10.03(2)(h)3. 3. Proparacaine HCl.
SPS 10.03(2)(h)4. 4. Tetracaine HCl.
SPS 10.03(2)(i) (i) Antibiotics.
SPS 10.03(2)(i)1. 1. Topical antibiotics.
SPS 10.03(2)(i)1.a. a. Aminoglycosides.
SPS 10.03(2)(i)1.b. b. Bacitracin.
SPS 10.03(2)(i)1.c. c. Cephalosporins.
SPS 10.03(2)(i)1.d. d. Ciprofloxacin HCl.
SPS 10.03(2)(i)1.e. e. Erythromycin.
SPS 10.03(2)(i)1.f. f. Gramicidin.
SPS 10.03(2)(i)1.g. g. Norfloxacin.
SPS 10.03(2)(i)1.h. h. Penicillins.
SPS 10.03(2)(i)1.i. i. Polymyxin B.
SPS 10.03(2)(i)1.j. j. Sulfonamides.
SPS 10.03(2)(i)1.k. k. Tetracyclines.
SPS 10.03(2)(i)1.L. L. Trimethoprim.
SPS 10.03(2)(i)1.m. m. Zinc sulfate.
SPS 10.03(2)(i)2. 2. Oral antibiotics.
SPS 10.03(2)(i)2.a. a. Erythromycin.
SPS 10.03(2)(i)2.b. b. Tetracycline.
SPS 10.03(2)(i)3. 3. Topical antiviral agents.
SPS 10.03(2)(i)3.a. a. Acyclovir.
SPS 10.03(2)(i)3.b. b. Idoxuridine.
SPS 10.03(2)(i)3.c. c. Trifluridine.
SPS 10.03(2)(i)3.d. d. Vidarabine.
SPS 10.03(2)(i)4. 4. Acyclovir, an oral antiviral agent.
SPS 10.03(2)(j) (j) Anti-inflammatory agents.
SPS 10.03(2)(j)1. 1. Oral non-steroidal anti-inflammatory agents.
SPS 10.03(2)(j)1.a. a. Fenoprofen.
SPS 10.03(2)(j)1.b. b. Ibuprofen.
SPS 10.03(2)(j)1.c. c. Ketoprofen.
SPS 10.03(2)(j)1.d. d. Naproxen.
SPS 10.03(2)(j)2. 2. Topical corticosteroid agents.
SPS 10.03(2)(j)2.a. a. Dexamethasone.
Down
Loading...
Loading...
Published under s. 35.93, Stats. Updated on the first day of each month. Entire code is always current. The Register date on each page is the date the chapter was last published.